PSA leads national Quality Use of Medicines agenda

The Pharmaceutical Society of Australia (PSA) is continuing to drive the national agenda on Quality Use of Medicines (QUM), securing involvement in 7 key projects under the Australian Government’s latest Quality Use of Diagnostics, Therapeutics and Pathology (QUDPT) grants.

These projects span key health priorities, including palliative care, polypharmacy, and equitable access to medicines, reinforcing PSA’s role in delivering best-practice guidance to healthcare professionals and consumers on improving safe and effective medicine use. 

‘Pharmacists integral to ensuring medicines are used appropriately’

PSA National President Associate Professor Fei Sim FPS says these projects reflect PSA’s commitment to ensuring all Australians receive the best possible health outcomes from their medicines. 

“Quality Use of Medicines is essential to safe and effective healthcare, and pharmacists are integral to ensuring medicines are used appropriately,” says A/Prof Sim.

“PSA is proud to support and partner in these vital projects, equipping pharmacists with the resources and education they need to help consumers make informed decisions about their medicines.”

Equipping profession with knowledge and skills

Of the 7 funded projects, 6 are healthcare professional-focused and 1 is dedicated to consumers.

Each initiative targets complex areas of medicine use and aims to strengthen pharmacists’ ability to support people from diverse backgrounds, including those with varying health literacy and cultural needs.

“These initiatives reinforce PSA’s role as the leader in pharmacist education, ensuring our profession is equipped with the knowledge and skills to support safe and effective medicine use,” says A/Prof Sim.

PSA’s leadership in medicine safety continues to drive national efforts to optimise medicine use and enhance patient care, supporting pharmacists in their roles as medicines experts.